Abstract
Methods and results
Sixteen CPVT1 patients performed a bicycle stress-test. Occurrence of VT triggers, i.e. premature ventricular complexes (PVC), depended on high heart rate, with individual thresholds. Atrial pacing above the individual PVC threshold in three patients did not induce PVCs.
The underlying mechanism for the clinical observation was explored using cardiomyocytes from mice with the RyR2-R2474S (RyR2-RS) mutation, which exhibit exerciseinduced VTs. While rapid pacing increased the number of Ca 2+ waves in both RyR2-RS and 
Introduction
Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) have an increased risk of sudden cardiac death due to ventricular arrhythmias. The mortality rate in untreated patients is 30-33% by the age of 35. [1] Current treatment options comprise β-adrenoceptor (βAR) antagonists and flecainide. [2] [3] [4] In earlier studies, as many as 46% of patients treated with βAR antagonists experienced breakthrough ventricular tachycardias (VT). [5] Flecainide offers effective added protection, but some patients still experience breakthrough VTs even on combined treatment. [2, 6, 7] In such patients, or patients who do not tolerate treatment with βAR antagonists, left cardiac sympathetic denervation can be an option. [8] [9] [10] If serious arrhythmic events occur despite optimal medical treatment, an implantable cardioverter defibrillator (ICD) is recommended, [8] but involves a risk of inappropriate shocks that can lead to patient distress and initiate VT and death. [3] Thus, new therapeutic strategies are needed, based on improved mechanistic insight. Stress testing of patients with CPVT, a central diagnostic strategy, shows a relationship between increasing heart rate and the occurrence of ventricular ectopy. [1, 5] More severe arrhythmias are often observed during high heart rates, such as sustained VTs appearing above a certain heart rate threshold. [1] βAR stimulation has been identified as an important factor for the development of arrhythmias in CPVT, and catecholamines, i.e. adrenaline [11] or isoprenaline (ISO), infusion [12] has been used as a stress test in CPVT. However, the diagnostic polymorphic non-sustained VT was only induced in 31% of patients with mutations pathogenic for CPVT. [5] In vivo, βAR stimulation increases heart rate, [13] but also has important non-chronotropic, i.e. heart-rate independent, effects on ventricular cardiomyocytes. On the other hand, increased heart rate has important effects on ventricular cardiomyocytes that are independent of βAR stimulation. Therefore, clarifying the relative importance of the heart rate and sympathetic activity for development of arrhythmias in CPVT could have important implications for diagnostic procedures and treatment strategies.
The focus of this study is CPVT type 1 (CPVT1), caused by mutations in the gene encoding the major intracellular cardiac Ca 2+ release channel, i.e. the ryanodine receptor 2 (RyR2). [14] RyR2 mutations in patients with CPVT1 cause pathological Ca 2+ leak from the sarcoplasmic reticulum (SR) in ventricular cardiomyocytes. [15, 16] Diastolic SR Ca 2+ leak may lead to delayed afterdepolarization (DAD) and trigger ventricular arrhythmias. [15] Theoretically, βAR stimulation and high heart rate can increase the amplitude of DADs, and promote triggered activity. [17] Accumulating evidence indicates that Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) could be a common mediator for the effects of both heart rate and βAR stimulation. [18, 19] CaMKII-dependent phosphorylation increases RyR2 channel opening probability, and thus the propensity for increased SR Ca 2+ leak and arrhythmogenic Ca 2+ waves. [20] Indeed, inhibition of CaMKII has proved beneficial in models of CPVT1. [19] We hypothesized that both heart rate and βAR stimulation contribute independently to the development of ventricular arrhythmias in CPVT1. We tested this hypothesis by combining observations from patients, cellular experiments and mathematical modeling.
Methods

Patients and patient data
Patients with genetically confirmed CPVT1 were included through the Department of Cardiology, Oslo University Hospital Rikshospitalet. The study was approved by the Regional Committee for Medical and Health Research Ethics (REC-South-East; REC ID 201772 / 2011-19297) , and conformed to the declaration of Helsinki. Written informed consent was obtained from all enrolled patients.
Sixteen patients performed standardized bicycle stress testing using a protocol previously described. [21, 22] Briefly, 12-lead ECGs were recorded during bicycling with increasing workload (Schiller CS-200 Ergo-Spiro, Diacor), starting at 25 W with stepwise increase until exhaustion. One to four tests per patient were included in the study. The threshold heart rate for ventricular arrhythmias in individual patients was defined as the heart rate at which premature ventricular complexes (PVC) occurred as bigeminy, couplets, or VT during stress testing. If patients did not develop any of these arrhythmic events, the threshold was set as the heart rate were single PVCs occurred.
Three patients with ICDs volunteered for an ICD-based pacing protocol following the bicycle stress test. In accordance with approval from the regional Ethical Committee, the pacing procedure was performed as part of the standard follow-up of these patients, and with a minimum of intervention. We wanted to assess the heart rate for start of ventricular arrhythmias before the pacing, to be able to choose the correct rate. Therefore, the exercise stress test had to be performed first and according to standard follow-up protocol. After cessation of the exercise test patients rested in the supine position until recovery of baseline heart rate, and for at least 10 minutes before the pacing procedure was performed as an add-on to their standard ICD control. Electrical pacing through the atrial electrode was performed for 30 s at 5-10 beats per minute (b.p.m.) above the individual threshold heart rate for ventricular arrhythmias identified during the bicycle stress test. A 12-lead ECG was recorded continuously during the ICD-pacing protocol.
Animal model of CPVT1
This project was approved by the Norwegian National Committee for Animal Welfare under the Norwegian Animal Welfare Act (FOTS ID: 7169, 5669), and conformed to the National Institute of Health guidelines (NIH publication No. 85-23, revised 1996, US). The generation of knock-in mice with a human CPVT1 causative RyR2-R2474S (RyR2-RS) mutation used in this study has been described previously. [16] 
Cellular experiments
Mice were anaesthetized in 2% isoflurane inhalation prior to sacrifice by cervical dislocation. Left ventricular cardiomyocytes were isolated using constant flow perfusion of the coronary arteries with collagenase-containing solution as previously described. [23] Whole 
Western blots
Hearts used for protein analysis were mounted on a modified Langendorff setup, and perfused through the aorta with a 37˚C modified Hepes-Tyrode's solution. 
Statistics
Results are reported as mean ± standard error of mean (SEM). Ca 2+ sparks data are reported by density plots using kernel density smoothing with a bandwidth of 0.3 in R software (version 3.0.2, The R Foundation for Statistical Computing). ANOVA or Nested ANOVA analysis with Bonferroni corrections were used as appropriate for analysis of RR-intervals in CPVT1 patients and cellular experiments, except analysis of Ca 2+ spark frequency for which Poisson analysis was used to adjust for a skewed distribution. P<0.05 was considered statistically significant.
Results
Ventricular arrhythmias in patients with CPVT1
were associated with increased heart rates during bicycle testing, but not during direct pacing
Sixteen patients (39±4 y, 56% women) diagnosed with CPVT1 were included. All patients were positive for CPVT-associated RyR2 mutations, two were probands and 14 were identified as part of family screening. Of these, 11 patients (69%) had symptoms associated with arrhythmias. All patients had been evaluated according to guidelines with echocardiography, and seven patients (44%) also with cardiac MR as part of the initial evaluation. (Table 1 ).
ECGs were recorded during bicycle stress tests from all patients. When available, we included results from multiple stress tests per patient. No patients exhibited PVCs or ventricular arrhythmias at rest, and the mean RR-interval at baseline was longer than the RR-interval immediately preceding any of the ventricular arrhythmias observed (p<0.05, Fig 1A-1C ). This illustration of the heart rate dependence of ventricular arrhythmias in CPVT1 was seen both in untreated patients and in patients treated with a beta-adrenoceptor antagonist ( Fig 1C) .
In addition to the sixteen patients included based on available data from bicycle stress testing, we included three patients harboring an ICD implanted due to CPVT1 (Table 1) . To test the importance of heart rate, we performed atrial pacing at rest in these patients. The pacing protocol was performed following bicycle testing after complete recovery to baseline heart rate. Atrial pacing was performed at 5-10 b.p.m. above the threshold for occurrence of PVCs during the bicycle stress test. None of the patients developed PVCs during pacing through the ICD (Fig 1D) .
βAR stimulation revealed an increased propensity for arrhythmogenic Ca 2+ release events in RyR2-RS mouse left ventricular cardiomyocytes
The propensity for diastolic Ca 2+ waves in RyR2-RS and WT left ventricular cardiomyocytes was measured in a 10 s period after stable Ca 2+ transients, which had been induced by field stimulation for 30 s (Fig 2A) . In absence of βAR stimulation, progressive increase of the pacing frequency raised the number of Ca 2+ waves in both RyR2-RS and WT (p<0.05), but did not reveal any differences between RyR2-RS and WT ( Fig 2B) . βAR stimulation, however, resulted in an increased number of Ca 2+ waves in RyR2-RS compared to WT both at 0.5 and 4 Hz pacing (p<0.05, Fig 2B) . Another measurement of Ca 2+ wave propensity is the time to occurrence of the first Ca 2+ wave upon secession of pacing, i.e. post-pacing Ca 2+ wave latency. This period decreased with pacing frequency in both RyR2-RS and WT (p<0.05), but was shorter in RyR2-RS than WT at 4 and 8 Hz both in the absence and presence of βAR stimulation (p<0.05, Fig 2C) .
To test the dose-response relationship between βAR stimulation and the number of Ca 2+ waves in the post-pacing period, cardiomyocytes were exposed to 0, 2, 20 and 200 nM ISO (4 Hz pacing, Fig 2D) . Increasing ISO concentrations resulted in increased frequency of Ca 2+ waves in both WT and RyR2-RS (p<0.05). Overall, the frequency of Ca 2+ waves was higher in RyR2-RS than WT across ISO concentrations (p<0.05).
To further characterize diastolic SR Ca 2+ release in RyR2-RS and WT, Ca 2+ sparks were recorded by confocal microscopy (Fig 3A and 3B ). In the absence of βAR stimulation, the propensity for Ca 2+ sparks was low in both RyR2-RS and WT (Fig 3C) , while during βAR stimulation the number of Ca 2+ sparks increased in both groups and was higher in RyR2-RS compared to WT (p<0.05, Fig 3D) . 
SR Ca
2+ content and threshold for Ca 2+ waves were lower in RyR2-RS than WT
The effects of pacing and βAR stimulation on Ca 2+ release and removal was further investigated by characterization of key aspects of Ca 2+ handling in isolated left ventricular cardiomyocytes. This was studied by pacing and caffeine induced Ca 2+ transients in RyR2-RS and WT (Fig 4A-4D) . In absence of βAR stimulation, RyR2-RS developed higher Ca 2+ transient amplitudes compared to WT at 4 Hz, while at 0.5 and 8 Hz, no significant differences were found (Fig 4E) . Following βAR stimulation, however, the Ca 2+ transient amplitude was lower in RyR2-RS compared to WT at all pacing frequencies (p<0.05, Fig 4E) . In line with this, SR Ca 2+ content in the absence of βAR stimulation was not significantly different in RyR2-RS and WT across pacing frequencies (Fig 4F) , while following βAR stimulation, SR Ca 2+ content was lower in RyR2-RS than WT overall (p<0.05), and at both 0.5 and 4 Hz (Fig   4F, p<0.05 ). These differences could not be explained by refilling of the SR, as cytosolic Ca 2+ removal rate, a key determinant for the Ca 2+ transient amplitude and SR Ca 2+ content, was not significantly different between RyR2-RS and WT (Fig 4G) . Next, threshold SR Ca 2+ content, defined as SR Ca 2+ content at which Ca 2+ waves occurred, was assessed (Fig 4D and 4H) . Overall, Ca 2+ waves developed at a lower SR Ca 2+ content in RyR2-RS than in WT both in the absence (p<0.05) and presence of βAR stimulation (p<0.05).
Measurements of abundance of Ca 2+ handling proteins did not reveal differences between RyR2-RS and WT
The abundance of key Ca 2+ handling proteins and phosphoproteins were quantified in left ventricular tissue from Langendorff perfused and paced hearts (Fig 5 and S1 Fig) . The only observed difference between the RyR-RS and WT was higher abundance of CaMKII phosphorylated at threonine286, i.e. autophosphorylated CaMKII, in RyR2-RS compared to WT at 8 Hz in the absence of βAR stimulation (p<0.05, Fig 5A) . No significant differences between RyR2-RS and WT were observed with regard to the abundance of RyR2 phospho-serine2808, RyR2 phospho-serine2814, PLB phospho-serine16 or PLB phospho-threonine17 at 4 or 8 Hz pacing (Fig 5B-5E ). SERCA2a abundance was also similar in RyR2-RS and WT (Fig 5F) . Importantly for quality control, βAR stimulation increased PLB phospho-serine16 in both RyR2-RS and WT (p<0.05, Fig 5B and 5D ).
Computer simulations support that pacing rate and βAR stimulation have independent effects on the propensity for Ca 2+ waves in both RyR2-RS and WT
A computational model of mouse ventricular cardiomyocyte electrophysiology and ion homeostasis was employed to deconvolve the factors underlying the effects of pacing frequency and βAR stimulation on Ca 2+ wave propensity. [24] With a 10% increase in RyR2 luminal Ca (Fig 6) : First, at 0.5 Hz βAR stimulation was necessary for Ca 2+ waves to occur in both RyR2-RS and WT (Fig 6A, left vs. right upper panels). Second, when all effects of CaMKII was removed or RyR2 phosphorylation level was kept at baseline, i.e. without effects of pacing or βAR stimulation, Ca 2+ wave propensity decreased in both RyR2-RS and WT (Fig 6A, red and green lines) . Third, higher pacing frequency increased the propensity for Ca 2+ waves by increased activation of CaMKII and phosphorylation of RyR2 (Fig 6B, left vs right panels) . However, higher frequency also increased the propensity for Ca 2+ waves by increasing SR Ca 2+ content, but only in WT ( Fig   6B) . Fourth, the main effect of CaMKII on Ca 2+ wave propensity depended on the time after cessation of pacing: Early after pacing, CaMKII activity and RyR2 phosphorylation were high, the SR Ca 2+ content at the time of the first Ca 2+ wave was lower in RyR2-RS (6A-C). Later in the diastolic period, the degree of RyR2 phosphorylation decayed more rapidly than the SR Ca 2+ refilling, and further Ca 2+ waves could only be generated by increased SR Ca 2+ content caused by reduced CaMKII-dependent RyR2 phosphorylation (Fig 6C) , and subsequent reduced SR Ca 2+ leak. With removal of CaMKII-dependent effects on Ca 2+ handling or by keeping RyR2 phosphorylation level at the baseline for the model, the threshold SR Ca 2+ content for waves was high even in the early phase of diastole, and time for refilling dominated the Ca 2+ wave latency (Fig 6A and 6C ).
Discussion
Our study confirms that ventricular arrhythmias in patients with CPVT1 are associated with increasing heart rate during exercise testing, as previously reported. [1, 21] However, comparisons of bicycle testing to ICD pacing indicate that increased heart rate by itself is not sufficient to induce arrhythmias. Experiments with ventricular cardiomyocytes corroborated this conclusion: while high pacing frequencies increased the number of Ca 2+ waves in both RyR2-RS and WT, βAR stimulation was necessary to reveal the increased propensity for Ca 2+ waves associated with CPVT1 in RyR2-RS. Computer simulations of CPVT1 cardiomyocytes further strengthened these findings, and show that although higher pacing frequency promotes Ca 2+ wave development, the effects of βAR stimulation on SR Ca 2+ release dynamics are necessary to allow increased propensity for Ca 2+ waves during high pacing frequencies in RyR-RS cardiomyocytes. Previous studies have established that βAR stimulation increases the degree of SR Ca 2+ leak and the propensity for arrhythmias in CPVT1, [26] while the effect of pacing frequency per se
has not yet been studied in this condition. Based on previous studies, we had reason to believe that frequency could promote SR Ca 2+ leak, and that this could be partly CaMKII-dependent:
In ventricular cardiomyocytes, both high heart rate and βAR stimulation increases the activity of CaMKII, which has been shown to increase SR Ca 2+ leak. [18, 19] The mechanism for activation of CaMKII during increased pacing frequencies is high cytosolic Ca 2+ concentration. [27] The importance of CaMKII-dependent SR Ca 2+ leak in CPVT1 is further indicated by the fact that CaMKII-inhibition by KN-93 or autocamtide-1 related inhibitory peptide reduced spontaneous Ca 2+ release in ventricular cardiomyocytes from mice with the CPVT1-causative
RyR2-R4496C mutation. [19] Our results support an important role for CaMKII in RyR2-RS, although the mechanism is somewhat more complex than previously hypothesized. SR Ca 2+ leak is highly dependent on SR Ca 2+ content. In our study, SR Ca RyR2-R4496C cardiomyocytes in which Ca 2+ transient amplitude was not changed by βAR stimulation. [19] One explanation for our findings is that the RyR2 is slightly sensitized even in absence of βAR stimulation, resulting in an increased fractional release even at baseline. Indeed, SR Ca 2+ threshold for Ca 2+ waves in RyR2-RS was lower even in absence of βAR , it is the combination of these two dynamic effects that determines when a Ca 2+ wave will occur in this model. βAR stimulation promotes Ca 2+ waves because it both increases RyR phosphorylation by CaMKII, and dramatically increases the rate of SR Ca 2+ refilling. Increased pacing frequency also exaggerates both of these effects, but more modestly. A potentially important observation from our computational model with regard to diastolic Ca 2+ release is that the effects of CaMKII may be highly dynamic in cardiac myocytes, even during an individual cardiac contraction-relaxation cycle, which might explain why an increase in CaMKII-dependent phosphorylation of RyR2-Ser2814 during ISO stimulation was not detected by immunoblotting. However, changes in RyR2-Ser2814 phosphorylation have been well documented in chronic disease models by previous studies. [18] While the relevance of the observations made from pause-induced release experiments (and simulations) to clinical exercise stress tests is limited, the finding that RyR2 phosphorylation is important in early diastole may help to explain why blockade of CaMKII alleviates the pro-arrhythmia associated with CPVT1-causative mutations. [19] The discussion above illustrates the complexity of Ca 2+ homeostasis in ventricular cardiomyocytes at the core of arrhythmia development in CPVT1. However, the complete understanding of arrhythmia development even in this monogenic disease requires even further levels of complexity as both βAR stimulation and heart rate also affects the propensity for DADs to trigger action potentials and the propensity for development of VT. [16, 28] These aspects are beyond the scope of our study. Also important are electrophysiological differences between the human and mouse heart for interpretation of our data: In humans, SR Ca 2+ content increases with increasing pacing frequencies, contributing to a positive force-frequency relationship; in contrast, mice exhibit a less steep or no increase in SR Ca 2+ content during increased pacing frequencies. [29] Furthermore, due to a 10-fold faster heart rate and shorter action potentials the mouse is different from the human heart. To capture spontaneous Ca 2+ release events occurring during diastole in isolated myocytes, experiments were performed at artificially slow pacing frequencies compared to in vivo heart rates for mice. Because relatively slow pacing can affect the probability of these events, further validation in human cardiomyocytes and in vivo models is warranted. In our study, direct observations of heart rate effects in patients were made in the ICDbased pacing procedure, which indicated that increased heart rate per se was not sufficient to induce arrhythmias. However, the pacing protocol have important limitations: F.ex., during the pacing protocol, heart rate was increased for a shorter time than during the bicycle exercise test. We can only speculate that this could affect CaMKII activation. Our results show that the untangling of the effects of cathecolamines and heart rate should be further pursued in future studies, including extended and comprehensive pacing procedures.
In conclusion, our clinical and experimental data, as well as computational modelling, show that increased heart rate and heart rate-independent effects of βAR stimulation on ventricular cardiomyocytes combine to increase the risk of arrhythmias, with βAR stimulation being the necessary factor to reveal the CPVT1 phenotype in RyR2-R2474S. These data supports that the mainstay of treatment for CPVT1 is antagonism of βAR stimulation in ventricular cardiomyocytes. 
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